Get the Stockscreener App
16.64
0.83%
-0.14
Pacira Biosciences Inc Stock (PCRX) Latest News
Connor Clark & Lunn Investment Management Ltd. Takes $1.21 Million Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Pacira BioSciences: Not Done Yet Despite Devastating Share Price Losses (NASDAQ:PCRX) - Seeking Alpha
Segall Bryant & Hamill LLC Takes Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Victory Capital Management Inc. Boosts Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
PCRX (Pacira BioSciences) Market Cap : $810.3 Mil (As of Nov. 25, 2024) - GuruFocus.com
(PCRX) On The My Stocks Page - Stock Traders Daily
Pacer Advisors Inc. Purchases 2,799,434 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Global Alpha Capital Management Ltd. Sells 49,560 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Empowered Funds LLC Takes $3.29 Million Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth - MSN
Janney Montgomery Scott LLC Acquires New Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Impax Asset Management Group plc Boosts Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
PCRXPacira BioSciences, Inc. Latest Stock News & Market Updates - StockTitan
Pacira Announces 104-Week Safety and Efficacy Data - GlobeNewswire
When (PCRX) Moves Investors should Listen - Stock Traders Daily
Pacira BioSciences, Inc. (NASDAQ:PCRX) Stock Holdings Lifted by Los Angeles Capital Management LLC - MarketBeat
Pacira BioSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Pacira BioSciences' SWOT analysis: stock faces patent challenges amid growth initiatives - Investing.com Canada
Pacira BioSciences Inc (PCRX) Stock Price Down 3.31% on Nov 12 - GuruFocus.com
Barclays Issues Pessimistic Forecast for Pacira BioSciences (NASDAQ:PCRX) Stock Price - MarketBeat
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences - GlobeNewswire
Pacira BioSciences to Present at Jefferies and Piper Sandler Healthcare Conferences | PCRX Stock News - StockTitan
Robeco Institutional Asset Management B.V. Invests $1.05 Million in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Pacira BioSciences Inc (PCRX) Worth Considering For The Next Few Weeks - Stocks Register
Pacira BioSciences' (PCRX) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Brokerages Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target at $24.20 - Defense World
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q3 2024 Earnings Call Transcript - Insider Monkey
This Pacira BioSciences Insider Reduced Their Stake By 85% - Simply Wall St
Evaluating Pacira BioSciences: Insights From 8 Financial Analysts - Benzinga
Royal Bank of Canada Forecasts Strong Price Appreciation for Pacira BioSciences (NASDAQ:PCRX) Stock - MarketBeat
Pacira Pharmaceuticals stock target increased post Q3 earnings report By Investing.com - Investing.com UK
Pacira BioSciences Inc (PCRX) Q3 2024 Earnings Call Highlights: - GuruFocus.com
Pacira BioSciences Inc (PCRX) Q3 2024 Earnings Call Highlights: Strong Financial Position ... - Yahoo Finance
Pacira BioSciences Reports Q3 2024 Earnings and Strategic Developments - TipRanks
Pacira BioSciences Inc (PCRX) Reports Q3 2024 Revenue of $168.6M, EPS Misses Estimates with $3.11 Loss - GuruFocus.com
Pacira BioSciences Reports Third Quarter 2024 Financial Results - The Manila Times
Pacira BioSciences Reports $168.6M Revenue, Hit by $163.2M Impairment Charge in Q3 | PCRX Stock News - StockTitan
Impax Asset Management Group plc Has $7.08 Million Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Insights into Pacira BioSciences's Upcoming Earnings - Benzinga
Pacira BioSciences Inc (PCRX) Q3 2024: Everything You Need To Kn - GuruFocus.com
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives $24.20 Consensus Target Price from Analysts - MarketBeat
Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings - GlobeNewswire
Trading (PCRX) With Integrated Risk Controls - Stock Traders Daily
Rice Hall James & Associates LLC Sells 730,288 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Pacira BioSciences (PCRX) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
Allspring Global Investments Holdings LLC Buys 93,497 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024 - GlobeNewswire
Assenagon Asset Management S.A. Buys 419,656 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Shawn Cross appointed as chief financial officer for Pacira Biosciences - Pharmafile
0.83%
1.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):